Voyager Therapeutics, Inc.
VYGR
$3.36
$0.010.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.42% | -66.83% | -93.03% | 433.79% | 509.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.42% | -66.83% | -93.03% | 433.79% | 509.48% |
| Cost of Revenue | -1.95% | 16.37% | 27.38% | 16.93% | 45.34% |
| Gross Profit | -1,000.67% | -230.69% | -141.25% | 73.59% | 86.14% |
| SG&A Expenses | 3.39% | 12.00% | -12.19% | -1.09% | 22.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.66% | 15.31% | 16.12% | 12.57% | 39.05% |
| Operating Income | -192.42% | -114.38% | -165.71% | 53.30% | 50.74% |
| Income Before Tax | -229.81% | -173.81% | -159.25% | 65.48% | 54.32% |
| Income Tax Expenses | -37.50% | 164.29% | -28.95% | 124.29% | -59.32% |
| Earnings from Continuing Operations | -229.18% | -173.80% | -161.15% | 65.08% | 54.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -229.18% | -173.80% | -161.15% | 65.08% | 54.34% |
| EBIT | -192.42% | -114.38% | -165.71% | 53.30% | 50.74% |
| EBITDA | -219.41% | -124.72% | -162.30% | 55.72% | 54.26% |
| EPS Basic | -223.85% | -167.94% | -146.40% | 73.53% | 65.57% |
| Normalized Basic EPS | -330.91% | -168.09% | -141.28% | 73.84% | 74.06% |
| EPS Diluted | -216.67% | -165.80% | -147.68% | 72.90% | 64.73% |
| Normalized Diluted EPS | -330.91% | -168.09% | -142.30% | 73.84% | 74.06% |
| Average Basic Shares Outstanding | 1.64% | 2.16% | 31.81% | 31.89% | 32.63% |
| Average Diluted Shares Outstanding | 1.64% | 2.16% | 28.61% | 31.89% | 32.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |